GUS (IL23p19) showed skin and joint improvement in PsA pts (naive and TNFi failures) at Q4W and Q8W. No new safety signals noted. https://t.co/m8lCISnKpK Plenary abs #807 #ACR19 @RheumNow https://t.co/LfdOBnalmw
Links:
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Act…
http://ow.ly/LEyt50wQjvE
Nov-10-2019
